aTyr Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022

Rhea-AI Summary

aTyr Pharma, Inc. (Nasdaq: LIFE) announced a corporate overview presentation by CEO Sanjay S. Shukla at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 10:00 AM EDT, located at the Lotte New York Palace Hotel. The event will feature one-on-one meetings with registered investors and a webcast available on the company’s website, with a replay lasting 90 days. aTyr focuses on first-in-class medicines derived from its proprietary tRNA synthetase platform, particularly its clinical-stage candidate, efzofitimod, for fibrotic lung disease.

SAN DIEGO , Sept. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 24^th Annual Global Investment Conference, which is scheduled to take place September 12 – 14, 2022, at the Lotte New York Palace Hotel in New York, NY.

Details of the presentation appear below:

Conference: H.C. Wainwright 24^th Annual Global Investment Conference
Date: Wednesday, September 14, 2022
Time: 10:00am EDT
Location: Lotte New York Palace Hotel, New York, NY

In addition to the presentation, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conference. A webcast of the event will be available on the Investor’s section of the company’s website at www.atyrpharma.com. Following the event, a replay of the presentation will be available on the aTyr website for at least 90 days.

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in fibrotic lung disease. For more information, please visit http://www.atyrpharma.com.

Contact:
Ashlee Dunston
Director, Investor Relations and Corporate Communications
adunston@atyrpharma.com

 

FAQ

What is the date and time of aTyr Pharma's presentation at the H.C. Wainwright conference?

aTyr Pharma will present on September 14, 2022, at 10:00 AM EDT.

Where is the H.C. Wainwright Global Investment Conference being held?

The conference is taking place at the Lotte New York Palace Hotel in New York, NY.

Who is presenting on behalf of aTyr Pharma at the conference?

CEO Sanjay S. Shukla will present a corporate overview for aTyr Pharma.

Will there be opportunities for one-on-one meetings with aTyr Pharma management?

Yes, company management will be available for one-on-one meetings with registered attendees.

How can I watch the aTyr Pharma presentation online?

The presentation will be webcast on the Investor's section of aTyr's website.

What is aTyr Pharma's primary focus in their research?

aTyr focuses on first-in-class medicines from its tRNA synthetase platform, particularly efzofitimod for fibrotic lung disease.